{"id":"https://openalex.org/W1999412153","doi":"https://doi.org/10.1007/s00280-002-0458-y","title":"A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer","display_name":"A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer","publication_year":2002,"publication_date":"2002-07-01","ids":{"openalex":"https://openalex.org/W1999412153","doi":"https://doi.org/10.1007/s00280-002-0458-y","mag":"1999412153","pmid":"https://pubmed.ncbi.nlm.nih.gov/12111104"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-002-0458-y","doi":"https://doi.org/10.1007/s00280-002-0458-y","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-002-0458-y","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042631007","display_name":"Christopher W. Ryan","orcid":"https://orcid.org/0000-0002-4259-1123","observed_orcids":["https://orcid.org/0000-0002-4259-1123","https://orcid.org/0000-0003-1757-8311"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Ryan","raw_affiliation_strings":["Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA. cryan@medicine.bsd.uchicago.edu","Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA. cryan@medicine.bsd.uchicago.edu","institution_ids":["https://openalex.org/I40347166"]},{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Everett Vokes","raw_affiliation_strings":["Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059219836","display_name":"Nicholas J. Vogelzang","orcid":"https://orcid.org/0000-0002-7665-6079","observed_orcids":["https://orcid.org/0000-0002-7665-6079"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas Vogelzang","raw_affiliation_strings":["Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071718298","display_name":"Linda A. Janisch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linda Janisch","raw_affiliation_strings":["Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102739970","display_name":"Ken Kobayashi","orcid":"https://orcid.org/0000-0003-1171-0000","observed_orcids":["https://orcid.org/0000-0003-1171-0000"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ken Kobayashi","raw_affiliation_strings":["Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068268371","display_name":"Mark J. Ratain","orcid":"https://orcid.org/0000-0002-0938-4392","observed_orcids":["https://orcid.org/0000-0002-0938-4392"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Ratain","raw_affiliation_strings":["Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA,","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.6951,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.65573242,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"50","issue":"1","first_page":"1","last_page":"5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.7265999913215637,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.7265999913215637,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.14820000529289246,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.009800000116229057,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/suramin","display_name":"suramin","score":1.0},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.75},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.9380000233650208},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7210000157356262},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9940000176429749},{"id":"https://openalex.org/keywords/neuropathy","display_name":"neuropathy","score":0.6470000147819519},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.8619999885559082},{"id":"https://openalex.org/keywords/anorexia","display_name":"anorexia","score":0.9049999713897705},{"id":"https://openalex.org/keywords/trough-concentration","display_name":"trough concentration","score":0.5910000205039978},{"id":"https://openalex.org/keywords/fixed-dosing","display_name":"fixed dosing","score":0.4480000138282776}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.9056670665740967},{"id":"https://openalex.org/C2776182878","wikidata":"https://www.wikidata.org/wiki/Q425946","display_name":"Suramin","level":3,"score":0.7606304883956909},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6896543502807617},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6150670647621155},{"id":"https://openalex.org/C188198153","wikidata":"https://www.wikidata.org/wiki/Q1613840","display_name":"Limiting","level":2,"score":0.5497076511383057},{"id":"https://openalex.org/C68387754","wikidata":"https://www.wikidata.org/wiki/Q7271585","display_name":"Schedule","level":2,"score":0.4722178280353546},{"id":"https://openalex.org/C2778654693","wikidata":"https://www.wikidata.org/wiki/Q254327","display_name":"Anorexia","level":2,"score":0.4202394187450409},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41655418276786804},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39462465047836304},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3443198502063751},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012449","descriptor_name":"Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013498","descriptor_name":"Suramin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013498","descriptor_name":"Suramin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013498","descriptor_name":"Suramin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-002-0458-y","doi":"https://doi.org/10.1007/s00280-002-0458-y","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-002-0458-y","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:12111104","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12111104","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1012815014","display_name":null,"funder_award_id":"CA 14599","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2256082572","display_name":null,"funder_award_id":"CA69852-07","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G88379001","display_name":"Phase I Clinical Trials of Anti-Cancer Agents","funder_award_id":"U01CA069852","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000865577","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA014599","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W1984568385","https://openalex.org/W2005709557","https://openalex.org/W2151232297","https://openalex.org/W2232475418","https://openalex.org/W2271098438","https://openalex.org/W2271214418"],"related_works":["https://openalex.org/W2401690152","https://openalex.org/W2271214418","https://openalex.org/W1840478974","https://openalex.org/W1870158638","https://openalex.org/W2312102879","https://openalex.org/W1567293882","https://openalex.org/W4234049104","https://openalex.org/W2013472383","https://openalex.org/W2090162658","https://openalex.org/W7042504499"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}